Study of AZD5991 alone or in combination with venetoclax in relapsed or refractory haematologic malignancies.

Trial Identifier: D6910C00001
Sponsor: AstraZeneca
NCTID:: NCT03218683
Start Date: August 2017
Primary Completion Date: July 2022
Study Completion Date: July 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
US, CA Orange, CA, US, 92868
US, CO Aurora, CO, US, 80045
US, GA Atlanta, GA, US, 30322
US, MA Boston, MA, US, 02215
US, MO Saint Louis, MO, US, 63110
US, New York New York, US, 10065
US, NY New Hyde Park, NY, US, 11042
US, NY New York, NY, US, 10065
US, OH Columbus, OH, US, 43210
US, OR Portland, OR, US, 97239
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030